Antibody-based cancer therapy
- 4 May 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 40 (21), 3655-3664
- https://doi.org/10.1038/s41388-021-01811-8
Abstract
Over the past 25 years, antibody therapeutics have emerged as clinically and commercially successful pharmaceuticals, rapidly approaching 100 Food and Drug Administration approvals with combined annual global sales exceeding $100 billion. Nearly half of the marketed antibody therapeutics are used in oncology. These antibody-based cancer therapies can be broken down into three categories based on their different mechanisms of action, i.e., (i) natural properties, (ii) engagement of cytotoxic T cells, and (iii) delivery of cytotoxic payloads. Both natural and engineered properties of the antibody molecule are founded on its highly stable and modular architecture. In this review we provide an overview and outlook of the rapidly evolving landscape of antibody-based cancer therapy.Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961)
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
This publication has 53 references indexed in Scilit:
- IL-2: The First Effective Immunotherapy for Human CancerThe Journal of Immunology, 2014
- Immunogenic Cell Death in Cancer TherapyAnnual Review of Immunology, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane moleculesNature Medicine, 2011
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab PasudotoxClinical Cancer Research, 2011
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Mining human antibody repertoiresmAbs, 2010
- Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificityProceedings of the National Academy of Sciences of the United States of America, 2002
- Clonal selection and learning in the antibody systemNature, 1996
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proceedings of the National Academy of Sciences of the United States of America, 1989